Abstract
HIV-infected individuals have excess rates of invasive pneumococcal disease. We investigated risk factors for nasopharyngeal pneumococcal colonization at baseline and after 9 months in 96 HIV patients immunized twice with 7- valent pneumococcal conjugate vaccine ±1mg CPG 7909. In total, 22 patients (23%) were colonized, 11 at baseline only, four at both baseline and 9 months, and seven at 9 months only. Compared to non-colonized patients, more colonized patients were smokers, had lower CD4+ nadir and had an AIDS-diagnosis. Immunization, antiretroviral treatment and the CPG adjuvant had no impact on colonization. These results suggest preventive strategies in addition to pneumococcal immunization.
Original language | English |
---|---|
Journal | Current H I V Research |
Volume | 10 |
Pages (from-to) | 252-5 |
Number of pages | 4 |
ISSN | 1570-162X |
Publication status | Published - 2012 |
Externally published | Yes |
Keywords
- AIDS-Related Opportunistic Infections
- CD4-Positive T-Lymphocytes
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Cohort Studies
- Colony Count, Microbial
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Nasopharynx
- Pneumococcal Infections
- Pneumococcal Vaccines
- Randomized Controlled Trials as Topic
- Risk Factors
- Smoking
- Streptococcus pneumoniae
- Vaccines, Conjugate